Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.

Key Points

• This study aims to assess the risk of secondary primary malignancies (SPMs) in patients with indolent non-Hodgkin lymphoma treated with bendamustine-rituximab.
• Analyzed patient outcomes over 5 years
• Conducted univariate and multivariable analyses
• Examined the association between the number of BR cycles and SPM risk
• BR patients showed a higher SPM risk at 5 years in univariate models
• No significant SPM risk was found in multivariable analysis
• More BR cycles were linked to a borderline increase in SPM risk